Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging
The investigators are testing the effectiveness of an experimental imaging technology known
as Diffuse Optical Spectroscopy Imaging in predicting the success of chemotherapy treatment
(shrinkage of tumor).
Diffuse optical spectroscopic imaging measurements are made with a laser breast scanner.
This bedside-capable system combines frequency-domain photon migration with steady-state
tissue spectroscopy to measure complete(broadband) near-infrared absorption and reduced
scattering spectra of breast tissue in vivo. DOSI measurements are made by placing the
hand-held probe on the tissue surface and moving the probe to discrete locations along a
grid pattern at 1.0 cm intervals. The portable high-bandwidth Frequency-Domain Photon
Migration instrument employs intensity-modulated diode lasers and conventional steady-state
lamps as sources and an avalanche photodiode as the detector. The time required to perform
an Frequency-Domain Photon Migration measurement depends on the desired precision and number
of sweeps.
Observational
Observational Model: Case-Only, Time Perspective: Prospective
Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response
up to 12 months
No
Bruce Tromberg, PhD
Principal Investigator
Beckman Laser Institute
United States: Institutional Review Board
NIH/NCRR P41-RR01192
NCT01257932
December 2010
December 2015
Name | Location |
---|---|
Beckman Laser Institute | Irvine, California 92612 |